This is a standard, non-contentious proxy filing. Monitor for the vote outcome on the capital increase and stock option plan, but no immediate action is required from traders.
Price Chart
Executive Summary
CRISPR Therapeutics AG filed a definitive proxy statement for its 2026 Annual General Meeting, seeking shareholder approval on routine matters including financial statements, board re-elections, executive compensation, and an increase to its capital band and conditional share capital. The filing is standard and routine, with no activist opposition or contentious proposals.
Key Financial Metrics
Key Facts
- Filing is a routine DEFA14A proxy statement for the 2026 Annual General Meeting.
- Board of Directors recommends approval of all 13 proposals.
- Proposals include re-election of board members, approval of financial statements, discharge of directors, and approval of the 2026 Stock Option and Incentive Plan.
- No activist opposition or dissident slate is present; this is a management solicitation.
- Recent insider activity shows 3 sells totaling $791K in the last 30 days.
Financial Impact
Routine financial and governance matters; no immediate financial impact.
Risk Factors
- Potential shareholder concerns over executive compensation or capital structure changes, though the board recommends approval.
- Recent insider selling could signal lack of confidence, but is not directly tied to this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-165164 |
| Document: 0001193125-26-165164-index-headers.html | 0001193125-26-165164 |
| Document: 0001193125-26-165164-index.html | 0001193125-26-165164 |
| Document: 0001193125-26-165164.txt | 0001193125-26-165164 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.01 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.01 (−1.74%) |
Oct 16, 2026 9d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (−2.06%) |
Oct 16, 2026 9d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (+2.06%) |
Oct 15, 2026 10d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.01 (−0.49%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.01 (−4.87%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.01 (−6.38%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.01 (+9.63%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.01 (−15.09%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.01 (−7.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers